Introduction and Objective Frequent exacerbations (2 exacerbations in the past year) is a prognostic factor in severe asthmatics and is associated with increased morbidity and mortality. Using clinical and transcriptomic data, we sought to characterise a clinical subtype of asthma associated with persistent frequent exacerbations (PFE) which is defined by frequent exacerbations for minimum 2 consecutive years. Methods Baseline and longitudinal clinical and transcriptomic data from 311 severe asthmatics from the U-BIOPRED study was analysed to find distinct clinical characteristics of the PFE group. The longitudinal data was collected 12-18 months after the baseline visit. We also sought to annotate the PFE group with gene set variation analysis (GSVA) using gene signatures associated with active viral infection and immune response. Results Out of 311 patients, 193 were frequent exacerbators (FE) at baseline. 109 (56.5%) of FE subjects at baseline remained FE at the longitudinal follow-up and were designated PFE. This group of patients had earlier-onset of asthma (25 [28] , mean ±SD) and higher eczema diagnosis (37.61% vs 28.22%) compared with infrequent and non-persistent exacerbators. However, they had lower atopy positive blood tests(57.80 vs 68.32%). These patients also had poor lung function and lower airway conductance with a lower mean Sgaw (0.72±0.6 vs 0.99±0.8, mean ±SD). The number of subjects taking oral corticosteroids (60.2 vs 37.6%) and xanthines (34.3 vs 12.6%) was greater in the PFE group. PFE patients were more poorly controlled (ACQ; 2.7±1.2 vs 2.0±1.1, mean ±SD) and had a worse quality of life (AQLQ; 4.2±1.1 vs 4.6±1.3, mean ±SD) with higher anxiety and depression (HADS; 14.0 ±7.9 vs 12.1±8.2, mean ±SD). GSVA analysis identified gene signatures associated with an active viral response to be differentially enriched amongst the PFE in nasal brushing samples. Conclusion This study identified a group of asthmatics, defined by PFE who have poorly managed and difficult-totreat asthma. It also identified a potential role of the minimally invasive nasal brushing sample to identify PFE and thus allow for early intervention and improvement in the morbidity and mortality in this group of patients. Background RSV is a ubiquitous pathogen causing severe disease in children and the elderly. There is as yet no licensed vaccine. SynGEM, a novel intranasal subunit vaccine based on the RSV F glycoprotein linked to an immunostimulatory bacterium-like-particle carrier, was previously shown in animal models to elicit durable immune responses both locally (nasal secretory IgA) and systemically (serum neutralising antibodies). Induction of mucosal as well as systemic antibodies may enhance protection and reduce transmission. This was the first-in-human phase 1 study of SynGEM in healthy volunteers. Methods MUC-SynGEM-001 was a randomised, placebo-controlled, phase 1 trial that enrolled healthy adults aged 18-49 years to evaluate the safety and tolerability of SynGEM. Forty-eight participants were randomly assigned to either the low-dose (140 mg F-protein-FP/2 mg BLPs) or high-dose group (350 mg F-protein-FP/5 mg BLPs) and received the vaccine or placebo in a 3:1 ratio. Primary safety outcomes included local or systemic, solicited or unsolicited adverse events (AE) within 28 days and incidence of vaccine-related serious adverse events (SAE) within 57 and 180 days post-vaccination. Antibodies were measured at baseline, day 29 and day 57. Results Overall incidence of solicited local (83.3% vs 83.3% vs 83.3%) and systemic (88.9% vs 72.2% vs 75.0%) AEs was similar between low-dose, high-dose and placebo groups. Most were of mild severity and only one was severe in a subject subsequently diagnosed with PCR-confirmed influenza A at the time of vaccination. The most common local side effects included nasal discomfort, rhinorrhea and loss of smell whereas fatigue, headache and myalgia were the most frequent systemic effects. Unsolicited AEs were primarily respiratory and reported by 33.3%, 55.6% and 33.3% of participants in the three respective groups. One SAE possibly related to the vaccine was recorded: a high-dose group participant reported persistent pulsatile tinnitus arising after the prime vaccination. Assessment of immunogenicity revealed significant dosedependent increases in serum and nasal antibodies. Conclusion SynGEM was generally well tolerated and the data showed that both local and systemic antibodies could be induced by intranasal delivery. However, one SAE was noted and further investigation as to whether intranasal subunit vaccination could be causal is required.
